Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks

AIMS: Type 2 diabetes mellitus (T2DM) is often associated with cardiovascular (CV) risk factors such as obesity, hypertension and dyslipidemia. The objective of this analysis was to evaluate potential effects of exenatide once weekly (ExQW), a GLP-1 receptor agonist, on glycaemic control and CV risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergenstal, R M, Li, Y, Porter, T K Booker, Weaver, C, Han, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593159/
https://www.ncbi.nlm.nih.gov/pubmed/23078638
http://dx.doi.org/10.1111/dom.12026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593159/
https://www.ncbi.nlm.nih.gov/pubmed/23078638
http://dx.doi.org/10.1111/dom.12026

Ejemplares similares